Jolley Asset Management LLC Has Lowered Glaxo Smithkline Ads (GSK) Holding by $3.24 Million as Share Value Rose

May 20, 2018 - By Nellie Frank

GlaxoSmithKline plc (NYSE:GSK) Logo

Jolley Asset Management Llc decreased its stake in Glaxo Smithkline Ads (GSK) by 99.7% based on its latest 2017Q4 regulatory filing with the SEC. Jolley Asset Management Llc sold 92,663 shares as the company’s stock rose 9.28% while stock markets declined. The institutional investor held 280 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $10,000, down from 92,943 at the end of the previous reported quarter. Jolley Asset Management Llc who had been investing in Glaxo Smithkline Ads for a number of months, seems to be less bullish one the $97.66B market cap company. The stock decreased 0.17% or $0.07 during the last trading session, reaching $40.03. About 3.13M shares traded or 7.11% up from the average. GlaxoSmithKline plc (NYSE:GSK) has declined 10.07% since May 20, 2017 and is downtrending. It has underperformed by 21.62% the S&P500.

Analysts await GlaxoSmithKline plc (NYSE:GSK) to report earnings on July, 25. They expect $0.78 earnings per share, up 11.43 % or $0.08 from last year’s $0.7 per share. GSK’s profit will be $1.90 billion for 12.83 P/E if the $0.78 EPS becomes a reality. After $0.68 actual earnings per share reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts 14.71 % EPS growth.

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Seekingalpha.com which released: “GlaxoSmithKline Plc (GSK) Q1 2018 Results – Earnings Call Transcript” on April 25, 2018, also Globenewswire.com with their article: “Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American …” published on May 16, 2018, Seekingalpha.com published: “FDA OKs expanded use for Glaxo’s Trelegy Ellipta” on April 24, 2018. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Streetinsider.com and their article: “Drugmaker GSK rings in more change as CFO heads for exit in 2019” published on May 09, 2018 as well as Investorplace.com‘s news article titled: “Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks” with publication date: May 17, 2018.

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 5 analysts covering GlaxoSmithKline (NYSE:GSK), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. GlaxoSmithKline had 6 analyst reports since November 27, 2017 according to SRatingsIntel. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Buy” rating given on Tuesday, January 16 by Barclays Capital. Cowen & Co maintained GlaxoSmithKline plc (NYSE:GSK) on Wednesday, February 14 with “Hold” rating. The firm has “Buy” rating by BNP Paribas given on Wednesday, April 4. The stock of GlaxoSmithKline plc (NYSE:GSK) earned “Hold” rating by Cowen & Co on Monday, December 11. The rating was upgraded by UBS on Monday, November 27 to “Buy”.

GlaxoSmithKline plc (NYSE:GSK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: